EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

Akihiro Yamada iD, Mary P Choules iD, Frances A Brightman iD, Shigeru Takeshita, Shinsuke Nakao iD, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry iD, David Orrell und 2 weitere

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.13297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Akihiro Yamada und 13 weiteren Autor:innen. Beteiligte Einrichtung: Astellas Pharma Inc., Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Oncolytic Virotherapy, Oncolytic Viruses, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT ‐bearing mice. In the CT26.WT ‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1 antibody was determined to be correlated with the timing of administration: greater efficacy was observed when hIL‐7/mIL‐12‐VV was administered before the anti‐PD‐1 agent instead of simultaneous administration. To identify an optimal dosing regimen for first‐in‐human clinical trials, a multiple model‐informed drug‐development (MIDD) approach was used through development of a quantitative systems pharmacology (QSP) model and an agent‐based model (ABM). All models were built and verified using available literature and preclinical study data. Multiple dosing scenarios were explored using virtual populations by altering the interval between hIL‐7/hIL‐12‐VV and pembrolizumab administration. In contrast with observations from preclinical studies, both the QSP and the ABM models demonstrated no antagonistic effect on the dose‐dependent antitumor efficacy of hIL‐7/hIL‐12‐VV by pembrolizumab in simulations of clinical therapy. Based on the MIDD strategy, it was recommended that the highest dose of hIL‐7/hIL‐12‐VV and pembrolizumab should be administered on the same day, but with pembrolizumab administration following hIL‐7/hIL‐12‐VV administration. Multiple different modeling approaches uniquely supported and informed the first‐in‐human clinical trial design by guiding the optimal dose and regimen selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedOncolytic VirotherapyOncolytic VirusesAntineoplastic Agents, ImmunologicalAnimalsMiceHumansInterleukin-12Vaccinia virusCell Line, TumorCombined Modality TherapyModels, BiologicalImmune Checkpoint InhibitorsXenograft Model Antitumor AssaysFemaleMice, Inbred BALB C

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, ImmunologicalInterleukin-12Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Astellas Pharma Inc., Tokyo, Japan.
  • Astellas Pharma Inc., Northbrook, Illinois, USA.
  • Physiomics Plc, Abingdon, UK.

ORCID-Profile: Akihiro Yamada, Mary P Choules, Frances A Brightman, Shinsuke Nakao, Hitesh Mistry, Christophe Chassagnole

Zitieren

APA

Yamada, A., Choules, M. P., Brightman, F. A., Takeshita, S., Nakao, S., Amino, N., Nakayama, T., Takeuchi, M., Komatsu, K., Ortega, F., Mistry, H., Orrell, D., Chassagnole, C., & Bonate, P. L. (2025). A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13297

Vancouver

Yamada A, Choules MP, Brightman FA, Takeshita S, Nakao S, Amino N, et al. A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13297

BibTeX
@article{Yamada2025,
  author = {Yamada, Akihiro and Choules, Mary P and Brightman, Frances A and Takeshita, Shigeru and Nakao, Shinsuke and Amino, Nobuaki and Nakayama, Takeshi and Takeuchi, Masato and Komatsu, Kanji and Ortega, Fernando and Mistry, Hitesh and Orrell, David and Chassagnole, Christophe and Bonate, Peter L},
  title = {A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.13297}
}
Kostenlos starten →